Amanta Healthcare Ltd
Amanta Healthcare Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Amanta Healthcare Ltd Q1 FY27 key numbers
- Revenue
- SteriPort Line 3 expected to contribute around INR120 crores annualized revenue, fully realized within 12 months post-commissioning (from August 2026).
As stated in Amanta Healthcare Ltd's Q1 FY27 earnings call transcript · published 25 Aug 2026. Reported figures, not investment advice.
The short version
SteriPort Line 3 expected to contribute around INR120 crores annualized revenue, fully realized within 12 months post-commissioning (from August 2026). SteriPort Line 3 commissioning expected by August 2026, with annualized peak revenue of INR110-120 crores achievable within 12 months of commissioning.
From Amanta Healthcare Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- SteriPort Line 3 expected to contribute around INR120 crores annualized revenue, fully realized within 12 months post-commissioning (from August 2026).
- SteriPort projected to generate roughly INR70 crores in top line during the 7 months remaining in FY27 and about INR425 crores revenue at peak utilization in FY28 including SVP.
- SVP facility to commence operations by March 2027, expected to drive growth in export-focused products like inhalation, ophthalmics, and preservative-free unit doses.
- SVP export revenues anticipated to comprise 60%-70% from advanced regulated markets (UK, Ireland, EU, Australia, Canada).
- Future growth drivers for FY27-FY29: inhalation products, ophthalmics, diluents in advanced markets.
- Focus on expanding sterile dosage forms, including exploring other packaging materials and drug delivery mechanisms beyond plastic.
2 more points from Amanta Healthcare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Amanta Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- SteriPort Line 3: Total capex of INR 90 crores; approx. INR 80 crores spent so far; commissioning expected by August 24-25, 2026.
- SVP Expansion: Total capex of INR 30 crores; about INR 7 crores spent so far; expected to be operational by March 2027.
- No immediate further capex planned for SteriPort beyond Line 3, despite demand-supply mismatch.
- Future exploration of other drug delivery mechanisms and packaging materials (e.g., glass) beyond current plastic packaging, with clarity expected by December 2026 or January 2027.
- Investment in formulation development team and new center under construction, intending 8-10 scientists and 3-4 regulatory affairs personnel for advanced markets.
2 more points from Amanta Healthcare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amanta Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Amanta Healthcare Ltd said on order book & pipeline — free account, 30 seconds.
What the Q1 FY27 call signalled
1 of 3 strong
Amanta Healthcare Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹77 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amanta Healthcar's management said in earlier quarters
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Amanta Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Amanta Healthcare Ltd Q1 FY27 results?
SteriPort Line 3 expected to contribute around INR120 crores annualized revenue, fully realized within 12 months post-commissioning (from August 2026). SteriPort Line 3 commissioning expected by August 2026, with annualized peak revenue of INR110-120 crores achievable within 12 months of commissioning.
What is Amanta Healthcare Ltd share price analysis?
Amanta Healthcare Ltd currently shows a below-average growth signal. The stock trades at a P/E of 39.6 with a market cap of ₹607 Cr. Investors should review the full earnings analysis for detailed insights.
Is Amanta Healthcare Ltd planning capital expenditure?
SteriPort Line 3: Total capex of INR 90 crores; approx.
Keep Amanta Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.